Poster

Efficacy and Safety of Iclepertin (BI 425809) in Patients with Schizophrenia: CONNEX, a Phase III Randomized Controlled Trial Program

Cognitive impairment is a major determinant of poor functional outcomes in schizophrenia. Currently, studies testing potential treatments for cognitive impairment have failed to demonstra...

Brianna Goldenstein , PhD;

10/26/2023

Efficacy and Safety of Paliperidone Palmitate 6-Month Formulation: A 3-Year Analysis in Adults With Schizophrenia

This analysis assessed the efficacy and safety of paliperidone palmitate 6-month (PP6M) in adults with schizophrenia who remained relapse free after a 1-year double-blind study (NCT033453...

Christoph U. Correll , MD;

10/26/2023

Efficacy and Safety of Seltorexant in Insomnia Disorder

In a double-blind, randomized, parallel-group, active- and placebo-controlled, 14-day, dose-finding study in adult/elderly subjects with insomnia disorder, the 10 mg and 20 mg dose groups...

Zhiheng Zhang , MS;

10/26/2023

Efficacy and Safety Outcomes When Transitioning to Paliperidone Palmitate 6-Month From Paliperidone Palmitate 1-Month Versus Paliperidone Palmitate 3-Month

This post hoc analysis of a non-inferiority study (NCT03345342) found that adult patients with schizophrenia who transition to palmitate 6-month (PP6M) from either paliperidone palmitate ...

Karen L. Johnston , PharmD;

10/26/2023

Efficacy and Safety Results from the Confirmatory Phase 3 Randomized, Placebo-Controlled Trial of MDMA-Assisted Therapy for Treatment of Chronic PTSD With at Least Moderate Severity

Posttraumatic stress disorder (PTSD) is a serious neuropsychiatric illness for which novel treatment options are urgently needed. This multi-site, randomized, double-blind, confirmatory p...

Berra Yazar-Klosinski , PhD;

10/26/2023

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder and Early-Stage Dementia: The MEMORY Study

The MEMORY study demonstrates the effectiveness of vortioxetine in clinically significantly improving depressive symptoms, cognitive performance, daily functioning, and HRQoL, as well as ...

Michael Adair , MBChB;

10/26/2023

Effects of Adjunctive Brexpiprazole on Patient Life Engagement in Major Depressive Disorder Analyzed by Baseline Clinical Characteristics: Post Hoc analysis of a Phase 4, Open-Label Study

This post hoc analysis of a Phase 4, open-label, 8-week study evaluated if baseline clinical characteristics may influence the effect of adjunctive brexpiprazole on patient life engagemen...

Francois Therrien , PharmD;

10/26/2023

Effects of Oxybate on Sleep, Sleep Architecture, and Disrupted Nighttime Sleep

We summarize clinical data on the effects of oxybates on sleep quality, sleep architecture, and disrupted nighttime sleep (DNS) in patients with narcolepsy. Key data from 4 studies on sod...

Thomas Roth , PhD;

10/26/2023

Differences in Stigma Surrounding Treatment for Generalized Anxiety Disorder and Major Depressive Disorder Across Race and Gender in College Students

This study explores the influence of race and sexual orientation on the stigma surrounding the treatment of GAD and MDD in a cohort of college students.

Sujay Singh ;

10/26/2023

Dosing and Treatment Patterns of Deutetrabenazine When Initiated Using a 4-Week Patient Titration Kit: Interim Results of the START Study

START is an ongoing, noninterventional, prospective, single-arm, 2-cohort (tardive dyskinesia [TD] and Huntington disease) study evaluating dosing and treatment patterns with deutetrabena...

Andrew J. Cutler , MD;

10/26/2023